Frontier Investigational Peptides Cluster
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
These are the “honest frontier” peptides: real, sometimes elegant mechanisms, but data that lives almost entirely in cells and animals — no human efficacy trials. Five (FOXO4-DRI, PNC-27, P21, PE-22-28, Adamax) sit at the experimental edge of longevity and other research. Two more (Dermorphin, Triptorelin) actually have more evidence but carry safety signals serious enough that OHM doesn't recommend them under any goal.
Honest read: everything here grades as insufficient-evidence and is encyclopedia-only — fascinating to understand, not something to run.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
What should I avoid combining — and what's synergistic?
The real caution here is bigger than stacking: Dermorphin is an opioid with dependence and breathing-suppression risk, and Triptorelin's actual effect is chemical castration — neither belongs in a consumer protocol. The rest are too early to have a known safety profile. Treat this whole page as “know about, don't use.”
How can I buy this?
We don't have a verified affiliate source for Frontier Investigational Peptides Cluster yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Why this is a cluster article — the honest frontier
This is the “honest frontier” reference: peptides that are scientifically interesting but early and thin — the kind a curious reader runs into on a vendor directory or a forum and wants a straight answer about. Five of them (FOXO4-DRI, PNC-27, P21, PE-22-28, Adamax) sit at the bleeding edge of peptide research: real mechanisms, mostly preclinical data, no human efficacy trials. The job here is to say plainly what each one is, what the science actually shows, label the tier honestly, and not inflate a mouse study into a recommendation.
Two more (Dermorphin, Triptorelin) belong in a different bucket. They have more evidence than the frontier five — but they carry safety signals serious enough that the KB does not recommend them under any consumer goal. The 0035 pass explicitly de-mapped both out of the “libido / sexual-function” category they’d been mis-tagged into — Triptorelin because its therapeutic effect is chemical castration, Dermorphin because it’s a µ-opioid agonist with dependence and respiratory-depression risk. That’s not gatekeeping — it’s information. Where a compound carries a genuine harm or dependence signal, we say so clearly, because being the source that tells the truth about the hard cases is the whole point.
Section 1 — Frontier / investigational
These five share a profile: a plausible, sometimes elegant mechanism; data that lives almost entirely in cells and animals; and a “research chemical, not for human use” regulatory status. Per the 0035 pass they all grade Tier D (insufficient basis for human use) and are kept encyclopedia-only — interesting to know about, not something the KB recommends.
FOXO4-DRI (FOXO4-DRI peptide)
What it is
FOXO4-DRI is a synthetic senolytic peptide — a compound designed to selectively clear senescent cells, the aged, dysfunctional “zombie” cells that stop dividing but refuse to die and accumulate with age, driving inflammation and tissue decline. “DRI” denotes a D-retro-inverso peptide: built from D-amino acids in reverse sequence, a design trick that makes it far more resistant to enzymatic breakdown than a normal peptide. It was developed in the lab of Peter de Keizer. It sits in the same longevity neighborhood as the telomerase/senescence work — cross-reference Epithalon for the Khavinson-school longevity angle.
Mechanism
In senescent cells, the transcription factor FOXO4 binds and sequesters p53, keeping those cells alive instead of letting them undergo apoptosis. FOXO4-DRI is designed to disrupt the FOXO4–p53 interaction, freeing p53 to trigger apoptosis selectively in senescent cells while sparing healthy ones. The appeal is targeting: clear the senescent burden, leave normal tissue alone.
Evidence — Tier D
The famous result is a single mouse study (Cell, 2017) showing senescent-cell clearance plus a measurable healthspan effect — restored fitness, fur density, and kidney function in aged and progeroid mice. That paper is the entire reason anyone is talking about this molecule.
Beyond it, the directory profile lists zero published clinical studies on PubMed and grades the evidence anecdotal — 0 studies cited, 0 human trials. So: a striking, well-known mouse result, a clean mechanistic story, and no human safety record at all.
Status
Research compound — not approved for human use, not eligible for compounding. Tier D / encyclopedia-only per the 0035 pass: promising mechanism, no human data. The senolytic category is one of the most-watched in longevity science; FOXO4-DRI specifically is still a one-landmark-study compound.
PNC-27
What it is
PNC-27 is an experimental anticancer peptide built around the p53 / HDM-2 axis. It fuses a fragment of the p53 protein (the residues that bind HDM-2) to a membrane-penetrating sequence, with the goal of killing cancer cells while sparing normal ones. The 0035 pass notes it’s frequently lumped into “anti-aging / longevity” directories but is really an anticancer / p53-restoration compound, not a longevity peptide proper.
Mechanism
The peptide carries an HDM-2 binding domain that recognizes membrane-bound HDM-2 — a form of the protein that cancer cells display on their plasma membrane but normal cells largely don’t. PNC-27 binds it, then disrupts the membrane and the mitochondria, causing necrosis selectively in cancer cells. The selectivity claim — kills cancer cells, spares normal cells — is the whole pitch and recurs across the in-vitro literature.
Evidence — Tier D for human use
The directory grades it “moderate” (17 studies, claims 3 human) but the underlying body is overwhelmingly cell-based, with one ex-vivo human-tissue study and one animal synergy study. The credible, on-topic citations (all):
- Sarafraz-Yazdi E, et al. — Ann Clin Lab Sci 2015 ex-vivo case-series — PNC-27 inhibited growth and was cytotoxic to patient-derived epithelial ovarian cancer cells in a dose-dependent way. 26663795
- Alagkiozidis I, et al. — Ann Clin Lab Sci 2017 — PNC-27 + paclitaxel showed a synergistic reduction in ovarian tumor growth in vivo. 28667027
- Pincus MR, et al. — Curr Pharm Des 2011 review — PNC-27/PNC-28 induce tumor-cell necrosis across multiple cancer types without harming normal cells. 21728981
- Krzesaj P, et al. — Ann Clin Lab Sci 2024 — PNC-27 binds membrane HDM-2 and disrupts mitochondria → cell necrosis. 38802154
- Thadi A, et al. — Anticancer Res 2020/2021 — selective necrosis of leukemia cells and colon-cancer stem cells via membrane HDM-2, sparing normal hematopoietic/epithelial cells. 32878773 · 33419797
There are zero randomized controlled trials and no completed human-efficacy trials. Source-integrity note: the directory’s “key studies” table for PNC-27 mistakenly included two unrelated papers (a Nigeria maternal-healthcare cohort and a Rome air-pollution study) — they have nothing to do with PNC-27 and are excluded here; treat the directory’s “3 human trials” count with caution.
Status
Research compound — not approved for human use. Tier D / encyclopedia-only per 0035: a genuinely interesting selective-cytotoxicity mechanism with real preclinical support, but no human clinical efficacy established and no place in a consumer-facing recommendation.
P21
What it is
P21 is a synthetic BDNF-mimetic peptide — designed to reproduce the neurotrophic action of brain-derived neurotrophic factor (BDNF), the brain’s master “grow and survive” signal for neurons. The 0035 pass describes it as CNTF-derived. (Note the name collision: “P21” here is the peptide, not the cell-cycle protein p21^CIP1.) It belongs to the cognitive cluster — pair with Cognitive peptides cluster — Dihexa, Pinealon, Cortagen and Semax for the better-evidenced nootropic peptides.
Mechanism
P21 is claimed to cross the blood-brain barrier and act as a BDNF mimetic, stimulating neurogenesis (formation of new neurons) and supporting cognitive function. The draw is that BDNF itself is a large protein that doesn’t cross the BBB well or survive in circulation; a small, stable mimetic that reproduces the signal would be valuable — if the activity holds up.
Evidence — Tier D
The directory lists 0 studies cited, 0 human trials, grading the evidence anecdotal, and states no published clinical studies were found on PubMed for P21. The 0035 pass grades it Tier D, citing preclinical neurogenesis data only, no human trials. — the specific preclinical reports behind the BDNF-mimetic claim are not attached in the captured profile.
Status
Research compound — not approved for human use. Tier D / encyclopedia-only. Plausible mechanism, essentially no captured primary evidence — frame as researcher-community interest with formal data still thin.
PE-22-28
What it is
PE-22-28 is a synthetic analog of spadin, an endogenous peptide that blocks the TREK-1 potassium channel. TREK-1 blockade is a well-known target for rapid-acting antidepressant research — TREK-1 knockout animals show a depression-resistant phenotype, which is what makes spadin and its analogs interesting.
Mechanism
PE-22-28 is designed to modulate (inhibit) TREK-1 channels, the mechanism associated with rapid antidepressant-like effects in preclinical models. The 0035 pass labels it a spadin-derived peptide, TREK-1 inhibitor, with the appeal being speed — a different and faster pathway than classic monoamine antidepressants.
Evidence — Tier D
The directory grades it anecdotal — 0 studies cited, 0 human trials and states no published clinical studies were found on PubMed. The 0035 pass grades it Tier D: preclinical antidepressant data, no human trials. — the spadin/TREK-1 preclinical antidepressant papers exist in the broader literature but are not attached in the captured profile.
Status
Research compound — not approved for human use. Tier D / encyclopedia-only. A scientifically clean mechanism (rapid antidepressant via TREK-1) with an entirely preclinical evidence base.
Adamax
What it is
Adamax is a synthetic nootropic peptide, described as a modified/enhanced variant in the Semax lineage — derived from a fragment of ACTH (adrenocorticotropic hormone). The 0035 pass identifies it specifically as an ACTH(4-10) fragment derivative. Semax itself is the better-evidenced relative — see Semax and Cognitive peptides cluster — Dihexa, Pinealon, Cortagen.
Mechanism
As a modified ACTH fragment, Adamax is claimed to influence neurotransmitter activity and BDNF levels, the same melanocortin-system / neurotrophic mechanism that underpins Semax’s nootropic reputation. The pitch is “Semax, but enhanced.”
Evidence — Tier D
The directory lists 0 studies cited, 0 human trials, grades it anecdotal, and states no published clinical studies were found on PubMed for Adamax. The 0035 pass grades it Tier D: minimal published data, encyclopedia-only. Of the frontier five, Adamax has the thinnest captured evidence — even the foundational ACTH-fragment work it leans on belongs to Semax, not to Adamax specifically.
Status
Research compound — not approved for human use. Tier D / encyclopedia-only. If a reader wants the evidenced version of this mechanism, Semax is the one with the human (Russian-school) data behind it.
Section 2 — Caution: peptides OHM does not recommend
The two below are different from the frontier five. They have more established science — one is FDA-approved, one is decades-studied — but each carries a safety signal serious enough that the KB does not map it to any consumer goal. This is stated as honest information so a reader who encounters these compounds understands exactly what they are and why the caution exists. Both were explicitly de-mapped from “libido / sexual-function” in the 0035 pass, where they had been mis-tagged.
Dermorphin — µ-opioid agonist (dependence + respiratory-depression risk)
What it is
Dermorphin is a naturally occurring opioid heptapeptide first isolated from the skin of Phyllomedusa (South American) frogs. It is an extraordinarily potent selective µ-opioid receptor agonist — the directory’s foundational pharmacology paper put it at ~752–2,170× the potency of morphine in animal models, and the 0035 pass summarizes it as ~40× morphine potency in practical human terms. It is best known publicly as a racehorse doping agent (“frog juice”), banned by WADA and racing authorities.
Mechanism
A selective µ-opioid receptor agonist with very high analgesic potency. It acts on the same receptor as morphine, fentanyl, and heroin — which is exactly why the caution applies: µ-opioid agonism brings the full opioid liability with it.
Evidence — Tier B
The directory grades it “emerging” (30 studies, 0 human trials) — meaning real animal pharmacology plus review-level human discussion, but no controlled human trials. The 0035 pass grades it Tier B (animal opioid-receptor data + illicit human use). Representative citations (all):
- Broccardo M, et al. — Br J Pharmacol 1981 — potent analgesia 752–2,170× morphine. 7195758
- Broccardo M, et al. — Eur J Pharmacol 1985 — dermorphin induced tolerance and physical dependence in rats, similar to morphine. 4040026 — this is the dependence signal, stated plainly.
- Hesselink JMK & Schatman ME — J Pain Res 2018 review — intrathecal dermorphin showed superior analgesic efficacy vs morphine in postoperative pain. 30538538
Why the caution —
Dermorphin is an opioid. A µ-opioid agonist of this potency carries respiratory depression, physical dependence, tolerance, and overdose risk — and dependence was demonstrated directly in the 1985 rat study above. Per the 0035 pass: “an opioid agonist with respiratory-depression + dependence profile does not belong in a consumer-recommendable surface under ANY goal. Encyclopedia-only as a curiosity”. The “sexual-function” directory tag it once carried was a categorization error; dermorphin has nothing to do with libido. OHM does not recommend it. It belongs in the encyclopedia as a real and pharmacologically remarkable compound — and as a clear example of why a “research peptide” label does not mean low-risk.
Status
Research compound, not approved for human use; the only real human use is illicit analgesia/doping. Tier B / safety RED / no consumer-goal mapping.
Triptorelin — GnRH agonist (chemical-castration / HPG-axis shutdown)
What it is
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (and marketed as Decapeptyl) for advanced prostate cancer, with established use in endometriosis and central precocious puberty. It is a legitimate, well-evidenced medication — but its therapeutic effect is the opposite of a libido or hormone-optimization peptide.
Mechanism — why it’s the opposite of what people assume
A GnRH super-agonist works in two phases. Initially it stimulates the pituitary (a transient “flare” of LH/FSH and sex-hormone output). But with continuous, non-pulsatile exposure it downregulates and desensitizes pituitary GnRH receptors, shutting down gonadotropin release and driving sex-hormone production to castrate levels. That sustained suppression is the therapy in prostate cancer — it’s chemical castration, used deliberately to starve hormone-driven tumors. For contrast, the peptides people actually use to restore the HPG axis (enclomiphene, hCG, gonadorelin’s pulsatile use, kisspeptin) work the other direction — see HPGA restoration — Enclomiphene, HCG, Gonadorelin, Kisspeptin (the four upstream-of-TRT levers).
Evidence — Tier A
This is the most-evidenced compound in the whole article. The directory grades it “strong” (30 studies, 19 human, up to Phase 4), and the 0035 pass grades it Tier A. Representative trials (all):
- Gravina A, et al. — ESMO Open 2025 (HOBOE, 10-yr update) n=1065 — triptorelin + letrozole improved disease-free survival in premenopausal HR+ early breast cancer. 39754976
- Li X, et al. — Adv Ther 2022 n=300 — triptorelin 3-month formulation non-inferior to 1-month for endometriosis. 35947347
- Yu X, et al. — Adv Ther 2024 n=66 — suppressed LH and slowed growth velocity in children with central precocious puberty. 39412628
The evidence is strong precisely for HPG-axis suppression — that’s the documented, intended effect.
Why the caution —
Per the 0035 pass: “This is the OPPOSITE of a libido peptide. The tag-derived ‘sexual-function’ mapping was wrong — triptorelin SUPPRESSES the HPG axis as its therapeutic effect… A consumer-facing builder cannot recommend a chemical-castration drug under ‘libido & sexual performance.’ Even with red-flagging it would be misleading”. Triptorelin is a powerful, legitimate prescription oncology/gynecology drug. It is not a self-directed performance or libido peptide, and using it as one would do the exact reverse of what a hormone-optimizing user wants. OHM does not recommend it for any consumer goal — it’s documented here so readers understand what it actually does. (Any clinical use of triptorelin is a prescription decision with a physician.)
Status
FDA-approved prescription medication (Trelstar); prescription-only. Tier A / safety RED for catalog purposes / no consumer-goal mapping per 0035.
Commercial note
None of these seven is in Alyve’s launch catalog, and there is no fabricated CTA in this article. This is deliberately an encyclopedia / authority piece — its job is to build the trust that converts elsewhere, by proving OHM will tell the truth about the thin and the risky compounds, not just sell the strong ones. The frontier five are catalog-expansion curiosities at best (Tier D); the two caution compounds are not recommendation candidates under any framing.
Sources
- · · · · · · (thepeptidelist.com directory captures, 2026-06-07)
- the deep-research grading that set every tier/safety/de-mapping call above (FOXO4-DRI, PNC-27, P21, PE-22-28, Adamax = Tier D encyclopedia-only; Dermorphin = Tier B / RED / de-mapped; Triptorelin = Tier A / RED / de-mapped)
- Key PMIDs (all pending citation pass): FOXO4-DRI Cell 2017; PNC-27 26663795, 28667027, 21728981, 38802154; Dermorphin 7195758, 4040026, 30538538; Triptorelin 39754976, 35947347, 39412628